| HOME >> BIOLOGY >> TECHNOLOGY |
MISSISSAUGA, ON, May 28 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that a poster presentation will report results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with head and neck cancer conducted by Biocon Limited (Bangalore, India), a licensee of CIMAB SA, YM's licensor, at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Florida from May 29 to June 2, 2009.
The poster entitled "A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer (abstract # 6041)" will be presented in the Head and Neck Cancer general poster session on Monday, June 1 from 8:00AM until 12:00PM on Level 2 in West Hall C.
About YM BioSciences
YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.
Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemorad
'/>"/>
| SOURCE YM BioSciences Inc. Copyright©2009 PR Newswire. All rights reserved |